<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751361</url>
  </required_header>
  <id_info>
    <org_study_id>AR-2000</org_study_id>
    <nct_id>NCT00751361</nct_id>
  </id_info>
  <brief_title>Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial</brief_title>
  <acronym>ART</acronym>
  <official_title>Prospective, Randomized, Controlled Clinical Study Evaluating the Efficacy of Rheopheresis for Dry Age-Related Macular Degeneration Dry AMD Treatment With Rheopheresis Trial - ART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apheresis Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apheresis Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose is to evaluate Rheopheresis for the treatment of patients with high-risk dry
      age-related macular degeneration and no therapeutic alternative. Rheopheresis is a method of
      therapeutic apheresis using the methodology of double filtration plasmapheresis to treat
      microcirculatory disorders.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is change in best corrected ETDRS-visual acuity (mean logMar change) after 7.5 months compared to baseline visual acuity for both groups.</measure>
    <time_frame>30 weeks (7.5 months)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Dry Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment group: Patients receive 10 Rheopheresis treatments within 17 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rheopheresis / double filtration plasmapheresis</intervention_name>
    <description>Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rheopheresis</other_name>
    <other_name>Double filtration plasmapheresis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 to 85 years old

          -  diagnosis of AMD in both eyes

          -  must have dry AMD in the study eye

          -  Study eyes with best-corrected ETDRS-visual acuity of 0.1-0.8

          -  peripheral veins allowing vascular access to establish the extracorporal circuit.

        Exclusion Criteria:

          -  other retinal or choroidal disorders than AMD

          -  optic nerve disease, glaucoma

          -  conditions that limit the view of the fundus

          -  acute bleeding in any eye

        General exclusion criteria for the treatment of Rheopheresis:

          -  anaemia

          -  haemorrhagic diathesis or coagulopathy

          -  diabetes

          -  serious acute or chronic kidney or liver failure

          -  hypotension systolic &lt; 100 mmHg

          -  chronic viral infection (HIV, hepatitis B, C)

          -  epilepsia, psychosis or dementia

          -  a malignant disease or any other condition with life expectancy &lt; 12 months

          -  known history of alcohol or drug abuse and long term serious nicotine abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank HJ Koch, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Frankfurt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Frankfurt Department of Ophthalmology</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2008</study_first_submitted>
  <study_first_submitted_qc>September 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2008</study_first_posted>
  <last_update_submitted>September 10, 2008</last_update_submitted>
  <last_update_submitted_qc>September 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Reinhard Klingel, Prof. Dr.</name_title>
    <organization>Apheresis Research Institute</organization>
  </responsible_party>
  <keyword>Rheopheresis</keyword>
  <keyword>Dry Age Related Macular Degeneration</keyword>
  <keyword>AMD</keyword>
  <keyword>apheresis</keyword>
  <keyword>microcirculation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

